[Federal Register: April 29, 2009 (Volume 74, Number 81)]
[Notices]               
[Page 19598]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr29ap09-126]                         

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

 
Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on February 2, 2009, Cambrex 
Charles City, Inc., 1205 11th Street, Charles City, Iowa 50616, made 
application by renewal to the Drug Enforcement Administration (DEA) to 
be registered as a bulk manufacturer of the basic classes of controlled 
substances listed in schedule II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Lisdexamfetamine (1205)....................  II
Methylphenidate (1724).....................  II
Phenylacetone (8501).......................  II
Codeine (9050).............................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Dextropropoxyphene, bulk (non-dosage forms)  II
 (9273).
Morphine (9300)............................  II
Thebaine (9333)............................  II
Sufentanil (9740)..........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for sale to its customers.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than June 29, 2009.

    Dated: April 17, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E9-9800 Filed 4-28-09; 8:45 am]

BILLING CODE 4410-09-P